Skip to Main Content

Suzanne Ostrand-Rosenberg, Ph.D.

Professor; Robert and Jane Meyerhoff Chair of Biochemistry

Suzanne Rosenberg

Office: BS 221
Phone: 410-455-2237
Lab: BS 204/205
Lab Phone: 410-455-2251
Email: srosenbe@umbc.edu

Research Group

 

Education

Postdoctoral, Johns Hopkins University, 1977
Ph.D., California Institute of Technology, 1975

Publications

RECENT and SELECTED EARLIER PUBLICATIONS

Parker, K.H., D.W. Beury, and S. Ostrand-Rosenberg, 2015. Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. In: Advances in Cancer Research, in press.

Parker KH, Sinha P, Horn LA, Clements VK, Yang H, et al. HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Res. 2014 Oct 15;74(20):5723-33. PubMed PMID: 25164013; PubMed Central PMCID: PMC4199911.

Beury, D.W., K.H. Parker, M. Nyandjo, P. Sinha, K.A. Carter, and S. Ostrand-Rosenberg, 2014. Cross-talk between myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. J. Leukoc Biol. 96:1109-1118. PMCID 4226789

Burke, M.C., M.S. Oei, N.J. Edwards, S. Ostrand-Rosenberg, and C. Fenselau, 2014. Ubiquitinated proteins in exosomes secreted by myeloid-derived suppressor cells. J. Proteome Res., 13:5965-5972. PMCID 4261954

Burke, M., W. Choksawangkarn, N. Edwards, S. Ostrand-Rosenberg, and C. Fenselau, 2014. Exosomes from myeloid-derived suppressor cells carry biologically active proteins. J. Proteome Res. 13:836-843. PMCID 3946337

Geng, D., S. Kaczanowski, A. Tsai, K. Younger, A. Ochoa, A Rapoport, S. Ostrand-Rosenberg, and E. Davila, 2015. TLR5 ligand-secreting T cells reshape the tumor microenvironment and enhance antitumor activity. Cancer Res. 75:1959-1971. PMCID 4433615

Ostrand-Rosenberg S, Horn LA, Haile ST. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol. 2014 Oct 15;193(8):3835-41. PubMed PMID: 25281753; PubMed Central PMCID: PMC4185425.

Haile ST, Horn LA, Ostrand-Rosenberg S. A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation. Cancer Immunol Res. 2014 Jul;2(7):610-5. PubMed PMID: 24819296; PubMed Central PMCID: PMC4082431.

Haile ST, Dalal SP, Clements V, Tamada K, Ostrand-Rosenberg S. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. J Immunol. 2013 Sep 1;191(5):2829-36. PubMed PMID: 23918985; PubMed Central PMCID: PMC3750086.

Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012 Mar 22;12(4):253-68. PubMed PMID: 22437938; PubMed Central PMCID: PMC3587148.

Chornoguz O, Gapeev A, O’Neill MC, Ostrand-Rosenberg S. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients. Mol Cell Proteomics. 2012 Nov;11(11):1457-67. PubMed PMID: 22942358; PubMed Central PMCID: PMC3494186.

Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA, et al. Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood. 2011 May 19;117(20):5381-90. PubMed PMID: 21450901; PubMed Central PMCID: PMC3109712.

Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, et al. Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. J Immunol. 2011 Jun 15;186(12):6822-9. PubMed PMID: 21555531; PubMed Central PMCID: PMC3377446.

Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009 Apr 15;182(8):4499-506. PubMed PMID: 19342621; PubMed Central PMCID: PMC2810498

Presentations

Tubingen, Germany at “Progress in Vaccination Against Cancer 15 (PIVAC 15)” Oct 2015: The continuing saga of understanding & improving anti-tumor immunity: from cancer vaccines to myeloid-derived suppressor cells & PDL1.

Karolinska Institutet, Stockholm, Sweden June 2015: Myeloid cells as an obstacle to cancer immunotherapy.

University of Utah, Aug 2015: Tumor-induced immune suppression: The last obstacle (or just another bump in the road) to global success of cancer immunotherapies?

Ljubljana, Slovenia at “4th International Cancer Immunotherapy and Immunomonitoring” conference Apr 2015: How to survive if you are a myeloid-derived suppressor cell (MDSC).

The Wistar Institute, Philadelphia, PA Apr 2015: Novel strategies for neutraling PD-1 pathway-mediated immune suppression in cancer.

UMBC Look Ahead Symposium Apr 2015: The Immune System vs. Cancer: Winners, Losers, and Complications.

NIH, The Vaccine Working Group Dec 2014: Myeloid-derived suppressor cells: Critical cells driving immune suppression in the tumor microenvironment.

MedImmune, Inc. Dec 2014: Novel Strategies for Neutralizing PD-1 Pathway-mediated Immune Suppression in Cancer.

National Harbor, Washington DC at “The Society for Immunotherapy of Cancer (SITC)” conference Nov 2014: Novel Strategies for Neutralizing PD-1 Pathway-mediated Immune Suppression in Cancer.

Baylor, Dallas TX Oct 2014: Inflammation, Alarmins, and Immune Suppression in the Tumor Microenvironment: It’s the RAGE.

Rome, Italy at “Progress in Vaccination Against Cancer 14 (PIVAC 14)” conference Sep 2014: Novel Strategies for Neutralizing PD-1 Pathway-mediated Immune Suppression in Cancer.

Loyola University of Chicago June 2014: Inflammation and Immune Suppression in the Tumor Microenvironment.

Karmanos Cancer Center, Wayne State University May 2014: Inflammation and Immune Suppression in the Tumor Microenvironment.

University of Michigan Apr 2014: Inflammation, Alarmins, and Immune Suppression in the Tumor Microenvironment: It’s the RAGE.

Whistler, Canada at “Keystone Conference Immune Evolution in Cancer” Mar 2014: Inflammation and Alarmins as Drivers of Immune Suppressive Myeloid Cells and Tumor Progression.

Regeneron Inc., Tarrytown, NY Mar 2014: Inflammation and Immune Suppression in Cancer.

Seven Springs, PA at “Translational Research Cancer Centers Consortium (TRC3)” conference: Inflammation-induced Immune Suppression in Cancer: It’s the RAGE.

NIH Feb 2014: Inflammation-induced Immune Suppression in Cancer: It’s the RAGE.

Asilomar, CA at “Midwinter Conference of Immunologists” Jan 2014: Inflammation-induced Immune Suppression in Cancer: It’s the RAGE.

Understanding Cancer
American Association of Cancer Research: Frontiers in Cancer Prevention
S. Ostrand-Rosenberg
Washington, DC Nov. 16-19, 2008
November 18, 2008

Tumor Induced Immune Suppression: The Inflammation Connection
American Association of Cancer Research: Tumor Immunology: New Perspectives
S. Ostrand-Rosenberg
Miami, FL, (Dec. 2-5, 2008)
December 4, 2008